We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01563432
First Posted: March 27, 2012
Last Update Posted: March 27, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
SK Chemicals Co.,Ltd.
  Purpose
This study was designed to compare and evaluate the pharmacokinetic characteristics of febuxostat after single oral administration of TMX-67 (test drug) and Feburic® tablet in healthy adults; and to evaluate safety and tolerance following a single-dose administration.

Condition Intervention Phase
Gout Drug: Feburic® Drug: TMX-67 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Febuxostat Between TMX-67 40mg 2 Tablets and Feburic® 80mg 1 Tablet in Healthy Male Volunteers

Resource links provided by NLM:


Further study details as provided by SK Chemicals Co.,Ltd.:

Primary Outcome Measures:
  • Pharmacokinetic characteristics (AUClast and Cmax) [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 14, 24 hours post-dose ]

Enrollment: 30
Study Start Date: January 2012
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: febuxostat (TR) Drug: Feburic®
80 mg*1 tablet
Drug: TMX-67
40 mg*2 tablets
Experimental: febuxostat (RT) Drug: Feburic®
80 mg*1 tablet
Drug: TMX-67
40 mg*2 tablets

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult males aged between 20 and 45 years
  • Subjects whose weight is 50 kg or more and BMI is between 18 and 29 kg/m2
  • Subjects who were voluntarily decided to participate in the study and provided written informed consent to observe the directions

Exclusion Criteria:

  • Medical history which may influence adsorption, distribution, metabolism, excretion of the drug
  • Clinically significant active chronic disease(s)
  • Persons who are deemed ineligible for the study by the investigator according to the clinical laboratory test results or for other reasons
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563432


Locations
Korea, Republic of
Korea University Anam Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
SK Chemicals Co.,Ltd.
Investigators
Principal Investigator: Ji-Young Park, M.D., Ph.D. Korea University Anam Hospital
  More Information

Responsible Party: SK Chemicals Co.,Ltd.
ClinicalTrials.gov Identifier: NCT01563432     History of Changes
Other Study ID Numbers: TMX-67_BE_I_2011
First Submitted: March 16, 2012
First Posted: March 27, 2012
Last Update Posted: March 27, 2012
Last Verified: February 2012

Keywords provided by SK Chemicals Co.,Ltd.:
crossover
pharmacokinetic
hyperuricemia
gout

Additional relevant MeSH terms:
Febuxostat
Gout Suppressants
Antirheumatic Agents